36
Participants
Start Date
June 30, 2015
Primary Completion Date
August 31, 2018
Study Completion Date
January 31, 2019
First line systemic treatment
Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
Radical treatment
to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
radiation therapy
Patients will receive dose and fraction regimen according to the metastatic site.
Chemoradiotherapy
Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
Instituto Nacional de Cancerologia, Mexico City
Instituto Nacional de Cancerologia de Mexico
OTHER